

Mutual Interference of Hemoglobin Glycation and Carbamylation

Thesis

Submitted for partial fulfillment of Master Degree

In

Medical Biochemistry and Molecular Biology

By

Sherihan Adel Abd El-Khalek

Demonstrator of Medical Biochemistry

and

Molecular Biology

Faculty of Medicine - Ain Shams University

Under supervision of

Prof. Abd-El-Rahman M.A.Hammouda

Professor of Medical Biochemistry and Molecular Biology

Faculty of Medicine - Ain Shams University

Dr. Enas Samir Nabih

Lecturer of Medical Biochemistry and Molecular Biology

Faculty of Medicine - Ain Shams University

**Faculty of Medicine
Ain Shams University
2013**

ACKNOWLEDGMENT

I thank ALLAH who granted me the ability to complete the work of this study.

I would like to express my supreme gratitude and great appreciation to **Prof. Dr. Abd-El-Rahman M.A.Hammouda**, Professor of Medical Biochemistry, Faculty of Medicine, Ain Shams University, for his continuous guidance, helpful supervision and valuable instructions throughout this study.

It is a pleasure to express my supreme gratitude and appreciation to **Dr. Enas Samir Nabih**, Lecturer of Medical Biochemistry, Faculty of Medicine, Ain Shams University, for her continuous guidance and close supervision through this study.

I am also deeply grateful to all the members of Medical Biochemistry Department, Ain Shams University, for their help and encouragement.

Contents

	Page
List of tables.....	I
List of figures.....	III
List of abbreviations.....	VI
Introduction.....	1
Aim of the work.....	4
Review of literature.....	
Diabetes Mellitus.....	5
Chronic Kidney Disease.....	21
Hemoglobin.....	35
Glycated hemoglobin.....	42
Carbamylated hemoglobin.....	53
High Performance Liquid Chromatography.....	58
Materials and methods.....	61
Results.....	75
Discussion.....	97
Conclusion	105
Recommendations	106
Summary.....	107
References.....	111
Arabic summary.....	-

List of Tables

NO.	Title	Page
1	Factors that can affect HbA1c.	49
2	Preparation and concentrations of calibration solutions of phenol.	69
3	Valine hydantoin (percent of reference phenol peak) obtained by incubation of washed RBCs with urea.	78
4	Comparison of valine hydantoin mean \pm SD obtained by incubation of washed RBCs with different concentrations of urea (mmol/L).	79
5	Valine hydantoin (percent of reference phenol peak) obtained by incubation of washed RBCs with 80 mmol/L urea and different concentrations of glucose (mmol/L).	83
6	Comparison of valine hydantoin mean \pm SD obtained by incubation of washed RBCs with 80 mmol/L urea and different concentrations of glucose (mmol/L).	84
7	Glycated hemoglobin (%) obtained by incubation of washed RBCs with different concentrations of glucose (mmol/L).	87
8	Comparison of glycated hemoglobin (%) obtained by incubation of washed RBCs with different concentrations of glucose (mmol/L).	87
9	Glycated hemoglobin (%) obtained by incubation of washed RBCs with 40 mmol/L urea and different concentrations of glucose (mmol/L).	90
10	Comparison of glycated hemoglobin (%) obtained by incubation of washed RBCs with 40 mmol/L urea and different concentrations of glucose (mmol/L).	90

List of Tables (cont.)

NO.	Title	Page
11	Glycated hemoglobin (%) obtained by incubation of washed RBCs with 80 mmol/L urea and different concentrations of glucose (mmol/L).	92
12	Comparison of glycated hemoglobin (%) obtained by incubation of washed RBCs with 80 mmol/L urea and different concentrations of glucose (mmol/L).	92
13	HbA1c (%) obtained by incubation of washed RBCs with no glucose and different concentrations of urea (mmol/L).	94
14	HbA1c (%) obtained by incubation of washed RBCs with 5 mmol/L glucose and different concentrations of urea (mmol/L).	94
15	HbA1c (%) obtained by incubation of washed RBCs with 10 mmol/L glucose and different concentrations of urea (mmol/L).	95
16	HbA1c (%) obtained by incubation of washed RBCs with 20 mmol/L glucose and different concentrations of urea (mmol/L).	95
17	HbA1c (%) obtained by incubation of washed RBCs with 40 mmol/L glucose and different concentrations of urea (mmol/L).	96
18	HbA1c (%) obtained by incubation of washed RBCs with different glucose and urea concentrations (mmol/L).	96

List of Figures

NO.	Title	Page
1	Amino acid sequences in α , β and γ chains derived from human hemoglobins.	39
2	Amadori rearrangement of glucose molecule.	43
3	Schematic representation of hemoglobin carbamylation.	57
4	HPLC apparatus.	60
5	Flowchart of the experiments used in this work.	62
6	Flowchart of hydrolysis of RBCs before testing in HPLC for determination of carbamylated hemoglobin	66
7	Standard curve of phenol (mg/L).	70
8	Representative HPLC tracing of valine hydantoin obtained by incubated valine and urea.	76
9	Representative HPLC tracing of injected phenol (210 mg/L).	76
10	Representative HPLC tracing of valine hydantoin obtained by incubated washed RBCs sample with urea followed by addition of phenol before injection.	80
11	Comparison of valine hydantoin mean (percent of reference phenol peak) obtained by incubation of washed RBCs with different concentrations of urea (mmol/L).	80
12	Mean valine hydantoin (percent of reference phenol peak) obtained by incubation of washed RBCs with different concentrations of urea (mmol/L).	81
13	Mean valine hydantoin (percent of reference phenol peak) obtained by incubation of washed RBCs with different concentrations of urea after subtracting 0 value.	81

List of Figures (cont.)

NO.	Title	Page
14	Representative HPLC tracing of valine hydantoin obtained by incubated washed RBCs sample with urea, glucose followed by addition of phenol (210 mg/L) before injection.	84
15	Comparison of valine hydantoin mean (percent of reference phenol peak) obtained by incubation of washed RBCs with 80 mmol/L urea and different concentrations of glucose (mmol/L).	85
16	Mean valine hydantoin (percent of reference phenol peak) obtained by incubation of washed RBCs with 80 mmol/L urea and different concentrations of glucose (mmol/L).	85
17	Comparison of valine hydantoin mean (percent of highest value) obtained by incubation of washed RBCs with 80 mmol/L urea and different concentrations of glucose (mmol/L).	86
18	Mean valine hydantoin (percent of highest value) obtained by incubation of washed RBCs with 80 mmol/L urea and different concentrations of glucose (mmol/L).	86
19	Comparison of glycated hemoglobin (%) obtained by incubation of washed RBCs with different concentrations of glucose (mmol/L).	88
20	Glycated hemoglobin (%) obtained by incubation of washed RBCs with different concentrations of glucose (mmol/L).	88
21	Comparison of glycated hemoglobin (%) obtained by incubation of washed RBCs with 40 mmol/L urea and different concentrations of glucose (mmol/L).	91

List of Figures (cont.)

NO.	Title	Page
22	Glycated hemoglobin (%) obtained by incubation of washed RBCs with 40 mmol/L urea and different concentrations of glucose (mmol/L).	91
23	Comparison of glycated hemoglobin (%) obtained by incubation of washed RBCs with 80 mmol/L urea and different concentrations of glucose (mmol/L).	93
24	Glycated hemoglobin (%) obtained by incubation of washed RBCs with 80 mmol/L urea and different concentrations of glucose (mmol/L).	93
25	Hemoglobin A1c after incubation of red blood cells with various concentrations of glucose and urea for five days.	94

Abbreviations

2hPG	2 hours plasma glucose
5HMF	5-hydroxymethylfurfural
ADA	American Diabetes Association
ARF	Acute renal failure
ACE	Angiotensin converting enzyme
BUN	Blood urea nitrogen
CarHb	Carbamylated hemoglobin
CDA	Canadian Diabetes Association
CO₂	Carbon dioxide
CO	Carbon monoxide
CVD	Cardiovascular disease
CHF	Chronic heart failure
CKD	Chronic kidney disease
COPD	Chronic obstructive pulmonary disorder
DM	Diabetes mellitus
DKA	Diabetic ketoacidosis
ESRD	End-stage renal disease
EPO	Erythropoiten
ECF	Extracellular fluid
FPG	Fasting plasma glucose
GDM	Gestational diabetes mellitus
GFR	Glomerular filtration rate
GHb	Glycated hemoglobin
GH	Growth hormone

HSP	Heat shock protein
Hb	Hemoglobin
HbA1c	Hemoglobin A1c
HPLC	High performance liquid chromatography
IDDM	Insulin Dependent Diabetes Mellitus
IGF-1	Insulin-like growth factor-1
IFN	Interferon gamma
IL-1	Interleukin-1
kDa	kilo Dalton
LBM	Lean body mass
MetS	Metabolic syndrome
NO	Nitric oxide
NKHS	Non-ketotic hyper-osmolar state
OGTT	Oral glucose tolerance test
O₂	Oxygen
PTMs	Post translational modifications
RBCs	Red blood cells
RAAS	Renin-angiotensin-aldosterone system
NaHCO₃	Sodium bicarbonate
TNF	tumor necrosis factor
T1DM	Type 1 diabetes mellitus
UKM	Urea kinetic modeling

INTRODUCTION

Diabetic nephropathy is a major complication of diabetes mellitus. Many studies have shown that in many regions of the world, including Egypt, diabetic nephropathy is the main cause of end-stage renal disease (*Ritz et al., 1999; Lee, 2003; Afifi et al., 2004*).

The high blood glucose concentration in patients with diabetes mellitus leads to abnormally high incidence of protein glycation. Post-translational modification of hemoglobin by non-enzymatic glycation occurs in the circulating red blood cells. Determination of glycated hemoglobin in diabetic patients is currently acknowledged as the most reliable indicator for assessment of retrospective glycemic control and the planning of clinical management (*Bernstein, 1987; Shojania et al., 2006; Guerin et al., 2007; Nicholls et al., 2008; Mannucci et al., 2009; Selvarai et al., 2009*).

Non-enzymatic carbamylation of hemoglobin is another type of post-translational modification, caused by blood urea. Impaired kidney function has always been associated with increase in blood urea concentration and carbamylation of proteins (*Hörkkö et al., 1992; Hörkkö et al., 1994; Balion et*

al., 1998; Berlyne, 1998). It has been documented that carbamylation contributes to uremic toxicity and that carbamylated proteins are implicated in the atherogenesis of chronic renal failure (*Hörkkö et al., 1994; Roxborough and Young, 1995*).

Carbamylated hemoglobin is the most simple, useful and reproducible index for measuring the carbamylation reaction in vivo. Its level reflects the intensity of uremic toxicity and it has a role in the clinical management of patients with renal failure similar to the way glycated hemoglobin is used in the monitoring of diabetic patients (*Flückiger et al., 1981; Oimomi et al., 1984; Davenport et al., 1993; Frazao et al., 1995; Davenport et al., 1996; Han et al., 1997; Tarif et al., 1997*).

Since both carbamylation and glycation reactions involve the free amino groups of the protein, especially the terminal valine residues in the case of hemoglobin, the possible interference of the two reactions should be considered (*Hammouda and Mady, 2001; Szymezak et al., 2009*). Would the kinetics of carbamylation remain the same in the presence of high blood glucose concentration, and would the glycation kinetics be the same in presence of high blood urea concentration? In this study, we tried to find an answer for the previous question. This is particularly important when

Introduction & Aim of the work

managing diabetic patients with chronic renal failure as in these patients; two related problems are monitored with two parameters that might be affected by each other.

AIM OF THE WORK

The aim of this work is to quantify the effect of hemoglobin glycation on the measured carbamylated hemoglobin and the effect of hemoglobin carbamylation on the measured glycated hemoglobin in hemoglobin obtained from normal subjects and incubated with varying concentrations of glucose and urea.

DIABETES MELLITUS (DM)

Diabetes is a metabolic disorder characterized by resistance to the action of insulin and/or insufficient insulin secretion (*Longo et al., 2002*).

The estimated number of adults with diabetes in the world will rise from 135 million in 1995 to 300 million in year 2025 and the prevalence in the world is expected to rise from 4% to 5.4% by the year 2025 (*Ltief et al., 2003*). It is estimated that by the year 2030, Egypt will have at least 8.6 million adults with diabetes. Diabetes is the eleventh most important cause of premature mortality in Egypt, and is responsible for 2.4% of all years of life lost. Similarly, diabetes is the sixth most important cause of disability burden in Egypt (*Shaw et al., 2010*).

Etiologic classification of diabetes mellitus: (*ADA, 2011*).

- I. Type 1 diabetes which results from β -cell destruction, usually leading to absolute insulin deficiency. It includes immune-mediated and idiopathic diabetes.
- II. Type 2 diabetes (may range from predominantly insulin resistance with relative insulin deficiency to a